{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T14:28:55Z","timestamp":1763389735949,"version":"build-2065373602"},"reference-count":39,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Institutes of Health (NIH), National Eye Institute (NEI)","doi-asserted-by":"publisher","award":["RO1EY025794","R24EY028767","1R01HL161087","1P01AG071463"],"award-info":[{"award-number":["RO1EY025794","R24EY028767","1R01HL161087","1P01AG071463"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["RO1EY025794","R24EY028767","1R01HL161087","1P01AG071463"],"award-info":[{"award-number":["RO1EY025794","R24EY028767","1R01HL161087","1P01AG071463"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RO1EY025794","R24EY028767","1R01HL161087","1P01AG071463"],"award-info":[{"award-number":["RO1EY025794","R24EY028767","1R01HL161087","1P01AG071463"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Recessive dystrophic epidermolysis (RDEB) is a rare, inherited, and currently incurable skin blistering disorder characterized by cyclically recurring wounds coexisting with chronic non-healing wounds. In a recent clinical trial, three intravenous infusions of skin-derived ABCB5+ mesenchymal stromal cells (MSCs) to 14 patients with RDEB improved the healing of wounds that were present at baseline. Since in RDEB even minor mechanical forces perpetually provoke the development of new or recurrent wounds, a post-hoc analysis of patient photographs was performed to specifically assess the effects of ABCB5+ MSCs on new or recurrent wounds by evaluating 174 wounds that occurred after baseline. During 12 weeks of systemic treatment with ABCB5+ MSCs, the number of newly occurring wounds declined. When compared to the previously reported healing responses of the wounds present at baseline, the newly occurring wounds healed faster, and a greater portion of healed wounds remained stably closed. These data suggest a previously undescribed skin-stabilizing effect of treatment with ABCB5+ MSCs and support repeated dosing of ABCB5+ MSCs in RDEB to continuously slow the wound development and accelerate the healing of new or recurrent wounds before they become infected or progress to a chronic, difficult-to-heal stage.<\/jats:p>","DOI":"10.3390\/cells12111468","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T01:36:28Z","timestamp":1684978588000},"page":"1468","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Kinetics of Wound Development and Healing Suggests a Skin-Stabilizing Effect of Allogeneic ABCB5+ Mesenchymal Stromal Cell Treatment in Recessive Dystrophic Epidermolysis Bullosa"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7846-3388","authenticated-orcid":false,"given":"Elke","family":"Niebergall-Roth","sequence":"first","affiliation":[{"name":"RHEACELL GmbH & Co. KG, 69120 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Dieter","sequence":"additional","affiliation":[{"name":"RHEACELL GmbH & Co. KG, 69120 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Daniele","sequence":"additional","affiliation":[{"name":"RHEACELL GmbH & Co. KG, 69120 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Fluhr","sequence":"additional","affiliation":[{"name":"RHEACELL GmbH & Co. KG, 69120 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Khokhrina","sequence":"additional","affiliation":[{"name":"RHEACELL GmbH & Co. KG, 69120 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Silva","sequence":"additional","affiliation":[{"name":"RHEACELL GmbH & Co. KG, 69120 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Ganss","sequence":"additional","affiliation":[{"name":"RHEACELL GmbH & Co. KG, 69120 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1312-0488","authenticated-orcid":false,"given":"Markus H.","family":"Frank","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA 02115, USA"},{"name":"Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA"},{"name":"Transplant Research Program, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA 02115, USA"},{"name":"School of Medical and Health Sciences, Edith Cowan University, Perth 6027, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Kluth","sequence":"additional","affiliation":[{"name":"RHEACELL GmbH & Co. KG, 69120 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13023-021-01811-7","article-title":"A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa","volume":"16","author":"Tang","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Tartaglia, G., Cao, Q., Padron, Z.M., and South, A.P. (2021). Impaired Wound Healing, Fibrosis, and Cancer: The Paradigm of Recessive Dystrophic Epidermolysis Bullosa. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22105104"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"737272","DOI":"10.3389\/fgene.2021.737272","article-title":"Dystrophic Epidermolysis Bullosa: Secondary Disease Mechanisms and Disease Modifiers","volume":"12","author":"Kiritsi","year":"2021","journal-title":"Front. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/bjd.20910","article-title":"The potential of gene therapy for recessive dystrophic epidermolysis bullosa","volume":"186","author":"Subramaniam","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s13555-021-00561-5","article-title":"Clinical Perspectives of Gene-Targeted Therapies for Epidermolysis Bullosa","volume":"11","author":"Welponer","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"adv00053","DOI":"10.2340\/00015555-3398","article-title":"Skin fragility: Perspectives on evidence-based therapies","volume":"100","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s13023-020-01467-9","article-title":"Small molecule drug development for rare genodermatoses-evaluation of the current status in epidermolysis bullosa","volume":"15","author":"Wally","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e14864","DOI":"10.15252\/emmm.202114864","article-title":"Deconstructing progressive inflammatory fibrosis in recessive dystrophic epidermolysis bullosa","volume":"13","author":"Ebens","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jaad.2019.11.038","article-title":"Phase I\/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa","volume":"83","author":"Rashidghamat","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1038\/jid.2015.158","article-title":"Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa","volume":"135","author":"Petrof","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e143606","DOI":"10.1172\/jci.insight.143606","article-title":"Intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients","volume":"6","author":"Lee","year":"2021","journal-title":"JCI Insight"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.celrep.2015.08.010","article-title":"ABCB5 Identifies Immunoregulatory Dermal Cells","volume":"12","author":"Schatton","year":"2015","journal-title":"Cell Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/stem.3022","article-title":"Newly defined ATP-binding cassette subfamily B member 5 positive dermal mesenchymal stem cells promote healing of chronic iron-overload wounds via secretion of interleukin-1 receptor antagonist","volume":"37","author":"Meyer","year":"2019","journal-title":"Stem Cells"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.jid.2021.10.026","article-title":"Angiogenin Released from ABCB5(+) Stromal Precursors Improves Healing of Diabetic Wounds by Promoting Angiogenesis","volume":"142","author":"Singh","year":"2021","journal-title":"J. Invest. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jcyt.2020.08.012","article-title":"Ex vivo-expanded highly pure ABCB5(+) mesenchymal stromal cells as Good Manufacturing Practice-compliant autologous advanced therapy medicinal product for clinical use: Process validation and first in-human data","volume":"23","author":"Kerstan","year":"2021","journal-title":"Cytotherapy"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"100067","DOI":"10.1016\/j.xjidi.2021.100067","article-title":"Allogeneic ABCB5(+) mesenchymal stem cells for treatment-refractory chronic venous ulcers: A phase I\/IIa clinical trial","volume":"2","author":"Kerstan","year":"2022","journal-title":"JID Innov."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1186\/s13287-022-03156-9","article-title":"Translational development of ABCB5+ dermal mesenchymal stem cells for therapeutic induction of angiogenesis in non-healing diabetic foot ulcers","volume":"13","author":"Kerstan","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/labinvest.2017.85","article-title":"Rapid generation of Col7a1(-\/-) mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells","volume":"97","author":"Webber","year":"2017","journal-title":"Lab. Invest."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e151922","DOI":"10.1172\/jci.insight.151922","article-title":"Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa","volume":"6","author":"Kiritsi","year":"2021","journal-title":"JCI Insight"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Dieter, K., Niebergall-Roth, E., Daniele, C., Fluhr, S., Frank, N.Y., Ganss, C., Kiritsi, D., McGrath, J.A., Tolar, J., and Frank, M.H. (2023). ABCB5+ mesenchymal stromal cells facilitate complete and durable wound closure in recessive dystrophic epidermolysis bullosa. Cytotherapy, in press.","DOI":"10.1016\/j.jcyt.2023.01.015"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Niebergall-Roth, E., Frank, N.Y., Ganss, C., Frank, M.H., and Kluth, M.A. (2023). Skin-Derived ABCB5+ Mesenchymal Stem Cells for High-Medical-Need Inflammatory Diseases: From Discovery to Entering Clinical Routine. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010066"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/s13287-020-01987-y","article-title":"Process data of allogeneic ex vivo-expanded ABCB5+ mesenchymal stromal cells for human use: Off-the-shelf GMP-manufactured donor-independent ATMP","volume":"11","author":"Ballikaya","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jcyt.2018.12.005","article-title":"In vivo safety profile and biodistribution of GMP-manufactured human skin-derived ABCB5-positive mesenchymal stromal cells for use in clinical trials","volume":"21","author":"Tappenbeck","year":"2019","journal-title":"Cytotherapy"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.jaad.2020.08.118","article-title":"Classification of 2 distinct wound types in recessive dystrophic epidermolysis bullosa: A retrospective and cohort natural history study","volume":"85","author":"Solis","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-019-1279-y","article-title":"The challenges of living with and managing epidermolysis bullosa: Insights from patients and caregivers","volume":"15","author":"Bruckner","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Schr\u00e4der, N.H.B., Korte, E.W.H., Duipmans, J.C., Stewart, R.E., Bolling, M.C., and Wolff, A.P. (2021). Identifying Epidermolysis Bullosa Patient Needs and Perceived Treatment Benefits: An Explorative Study Using the Patient Benefit Index. J. Clin. Med., 10.","DOI":"10.3390\/jcm10245836"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s13023-022-02461-z","article-title":"A prospective short-term study to evaluate methodologies for the assessment of disease extent, impact, and wound evolution in patients with dystrophic epidermolysis bullosa","volume":"17","author":"Paller","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/stem.2614","article-title":"Concise Review: MSC Adhesion Cascade-Insights into Homing and Transendothelial Migration","volume":"35","author":"Nitzsche","year":"2017","journal-title":"Stem Cells"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.isci.2019.05.004","article-title":"Mesenchymal Stromal Cell Homing: Mechanisms and Strategies for Improvement","volume":"15","author":"Ullah","year":"2019","journal-title":"iScience"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/stem.3356","article-title":"ABCB5+ dermal mesenchymal stromal cells with favorable skin homing and local immunomodulation for recessive dystrophic epidermolysis bullosa treatment","volume":"39","author":"Riedl","year":"2021","journal-title":"Stem Cells"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.18632\/aging.100755","article-title":"Transcriptome and ultrastructural changes in dystrophic epidermolysis bullosa resemble skin aging","volume":"7","author":"Breitenbach","year":"2015","journal-title":"Aging"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e14392","DOI":"10.15252\/emmm.202114392","article-title":"Pro-inflammatory immunity supports fibrosis advancement in epidermolysis bullosa: Intervention with Ang-(1\u20137)","volume":"13","author":"Bernasconi","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/stem.2417","article-title":"Suppression of neutrophil-mediated tissue damage-a novel skill of mesenchymal stem cells","volume":"34","author":"Jiang","year":"2016","journal-title":"Stem Cells"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/1153427-S0-000000000-00000","article-title":"A case of dystrophic epidermolysis bullosa improved with etanercept for concomitant psoriatic arthritis","volume":"11","author":"Gubinelli","year":"2010","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1546-0096-9-13","article-title":"An unusual case of epidermolysis bullosa complicated by persistent oligoarticular juvenile idiopathic arthritis; lessons to be learned","volume":"9","author":"Maritsi","year":"2011","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.15252\/emmm.201505061","article-title":"Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms","volume":"7","author":"Thriene","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.det.2009.10.011","article-title":"Type VII collagen: The anchoring fibril protein at fault in dystrophic epidermolysis bullosa","volume":"28","author":"Chung","year":"2010","journal-title":"Dermatol. Clin."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1172\/JCI34292","article-title":"A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy","volume":"118","author":"Fritsch","year":"2008","journal-title":"J. Clin. Invest."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/mt.2015.58","article-title":"High Local Concentrations of Intradermal MSCs Restore Skin Integrity and Facilitate Wound Healing in Dystrophic Epidermolysis Bullosa","volume":"23","author":"Mezger","year":"2015","journal-title":"Mol. Ther."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/11\/1468\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:41:30Z","timestamp":1760125290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/11\/1468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,24]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["cells12111468"],"URL":"https:\/\/doi.org\/10.3390\/cells12111468","relation":{},"ISSN":["2073-4409"],"issn-type":[{"type":"electronic","value":"2073-4409"}],"subject":[],"published":{"date-parts":[[2023,5,24]]}}}